Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of CD19-Targeted EGFRt/19-28z/4-1BBL CAR T Cells in Relapsed/Refractory CD19+ Hematologic Malignancies
NCT03085173Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2017
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EGFRt/19-28z/4-1BBL CAR T cells in chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) and 3 more, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 30 days. Started Mar 2017; status: active, not recruiting.
02
Drugs
EGFRt/19-28z/4-1BBL CAR T cells
03
Conditions
chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03085173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03085173.